Each Film coated tablet of ZINAROX® 500 contains:

• Cefuroxime 500 mg (as Cefuroxime axetil).

 Each Film coated tablet of ZINAROX® 250 contains:

• Cefuroxime 250 mg (as Cefuroxime axetil).

 Each Film coated tablet of ZINAROX® 125 contains:

• Cefuroxime 125 mg (as Cefuroxime axetil).

ZINAROX® is indicated in the following infections caused by susceptible organisms :

• Infections of upper respiratory tract for example, ear, nose, throat infections, such as otitis media, sinusitis and pharyngitis.
• Infections of lower respiratory tract for example, acute and chronic bronchitis, and pneumonia.
• Infections of genito-urinary tract for example, pyelonephritis, cystitis and urethritis.
• Infections of skin and soft-tissues for example, furunculosis, pyoderma and impetigo.

ZINAROX® is contraindicated in patients with known hypersensitivity to the Cephalosporins antibiotics.

• Probenecid competes for renal tubular secretion with ZINAROX® resulting in higher and more prolonged plasma concentrations of cefuroxime.

• ZINAROX® should be administered with caution during the early months of pregnancy.
• Cefuroxime is excreted in breast milk, and consequently caution should be exercised when ZINAROX® is administered to a nursing mother.

Generally mild and transient in nature:

• As with other Cephalosporins, there have been rare reports of hypersensitivity reactions including (skin rashes, urticaria, pruritis, drug fever and very rarely anaphylaxis).
• Gastrointestinal disturbances, including (diarrhoea, nausea, and vomiting) .

Diarrhoea, although uncommon, is more likely to be associated with higher doses of ZINAROX®.

• Headache has been reported.
• Eosinophilia and transient increases of hepatic enzyme levels have been noted during ZINAROX® therapy

Adults:

• For mild to moderate RTIs (e.g. Bronchitis): 250mg twice daily.
• For more severe LRTIs (pneumonia) : 500mg twice daily.
• For UTIs: 125mg twice daily is usually adequate.
• In pyelonephritis: the recommended dose is 250mg twice daily. 
• Uncomplicated gonorrhea:  a single dose of 1g is recommended.

children:

• The usual dose is 125mg twice daily. 

Otitis Media:

• Children < 2 years :125mg twice daily.
• Children > 2 years : 250mg twice daily.

Note:

• ZINAROX® Tablets should not be crushed and are therefore unsuitable for children under 5 years of age.
• No special precautions are necessary in patients with renal impairment or on renal dialysis or in the elderly at dosages up to the normal maximum of 1g per day.

• As with other antibiotics, prolonged use of ZINAROX® may result in the overgrowth of non-susceptible organisms (eg., Candida, Enterococci, Clostridum difficile), which may require interruption of treatment.
• Pseudomembranous colitis has been reported with the use of broad-spectrum antibiotics, therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use.
• Special care is indicated in patients who have experienced an anaphylactic reaction to penicillins.
• ZINAROX® should be given with caution to patients receiving concurrent treatment with potent diuretics because these diuretics are suspected of adversely affecting renal function.
• False positive reactions may occur if using methods depending on copper reduction eg. Fehling’s, Benedict’s, solutions and Clinitest. There for enzyme-based tests should be used.

ZINAROX® 500 mg ,250 mg &125 mg Tablets:

• (Blister of 5 tablets, Pack of two blisters).

• Store the drug in a dry place at a temperature below 30o C.
• ZINAROX® for Oral suspension, once reconstituted, must be stored in a refrigerator and used within one weak .